董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mary Garrett | 女 | Independent Director | 68 | 33.01万美元 | 1.01 | 2026-05-19 |
| Eileen J. Voynick | 女 | Independent Director | 72 | 31.85万美元 | 0.85 | 2026-05-19 |
| Edward P. Bousa | 男 | Independent Director | 67 | 30.32万美元 | 1.15 | 2026-05-19 |
| Bruce E. Scott | 男 | Independent Director | 70 | 32.56万美元 | 2.25 | 2026-05-19 |
| Kaushik Ghoshal | 男 | Independent Director | 57 | 29.81万美元 | 0.81 | 2026-05-19 |
| Randall A. Lipps | 男 | Director,Chairman of the Board,Chief Executive Officer and President | 69 | 753.19万美元 | 93.60 | 2026-05-19 |
| Robin G. Seim | 男 | Independent Director | 67 | 32.36万美元 | 4.69 | 2026-05-19 |
| Joanne B. Bauer | 女 | Lead Independent Director | 70 | 35.51万美元 | 3.78 | 2026-05-19 |
| Mark W. Parrish | 男 | Independent Director | 70 | 32.24万美元 | 5.84 | 2026-05-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Baird Radford | 男 | Executive Vice President and Chief Financial Officer | 56 | 151.35万美元 | 未持股 | 2026-05-19 |
| Nnamdi Njoku | 男 | Executive Vice President and Chief Operating Officer | 49 | 400.51万美元 | 未持股 | 2026-05-19 |
| Corey J. Manley | 男 | Executive Vice President and Chief Legal and Administrative Officer | 48 | 245.60万美元 | 2.44 | 2026-05-19 |
| Randall A. Lipps | 男 | Director,Chairman of the Board,Chief Executive Officer and President | 69 | 753.19万美元 | 93.60 | 2026-05-19 |
| Brian H. Nutt | 男 | Vice President, Chief Accounting Officer and Corporate Controller | 56 | 未披露 | 未持股 | 2026-05-19 |
董事简历
中英对照 | 中文 | 英文- Mary Garrett
-
Mary Garrett，曾担任IBM Global Sales and Distribution的副总裁，负责营销和沟通，领导地理营销团队、行业全球营销、企业和中型企业业务设计、数码销售和现场支持。此外，她曾担任IBM的咨询委员会的秘书，在那里她推动IBM全球最大的在线学术交流协会的对话，也曾担任the CMO Council的秘书，在那里她促进与世界领先的营销人员的最佳实践交流。此前，她曾领导IBM Global Technology Services的全球营销。她任职于the American Marketing Association（全球专业协会，拥有30000多名成员）的董事会，在那里她也担任财务副总裁兼秘书。她也是美国W.O.M.E.N。（专业开发团队，旨在提升有前途的职业女性）的活跃导师。
Mary Garrett has served as a director of Omnicell since May 2022. Ms. Garrett is currently the President of M. Power Coaching and Consulting, LLC, a firm focused on developing executive leaders and helping organizations align brand and culture, customer experience and employee engagement for positive impact on business vitality and growth. Ms. Garrett has held this position since June 2018. From September 2008 until December 2015, Ms. Garrett served as the chief marketing officer, global markets at International Business Machines Corporation ("IBM"), a leading global provider of technology products and services. Prior to that, Ms. Garrett served in key positions of increasing authority and responsibility upon joining IBM in 1981 through August 2008. Ms. Garrett currently serves as a director of PROCEPT BioRobotics Corp., a surgical robotics company, and has served on the board of this company and as chair of its nominating and governance committee since December 2021. Ms. Garrett previously served as a director of Ethan Allen Interiors, Inc., a leading interior design company, manufacturer and retailer in the home furnishings marketplace, from January 2016 until November 2021, and was a member of the Audit Committee. She has also served as a director of Hillrom Corporation (subsequently acquired by Baxter International, Inc.), a global medical technology company, from March 2017 until December 2021, and was chair of the Nominating/Corporate Governance Committee and a member of the Audit Committee. Ms. Garrett received a B.S. in bio medical engineering from Boston University and an M.S. in bio electrical engineering from Brown University. - Mary Garrett，曾担任IBM Global Sales and Distribution的副总裁，负责营销和沟通，领导地理营销团队、行业全球营销、企业和中型企业业务设计、数码销售和现场支持。此外，她曾担任IBM的咨询委员会的秘书，在那里她推动IBM全球最大的在线学术交流协会的对话，也曾担任the CMO Council的秘书，在那里她促进与世界领先的营销人员的最佳实践交流。此前，她曾领导IBM Global Technology Services的全球营销。她任职于the American Marketing Association（全球专业协会，拥有30000多名成员）的董事会，在那里她也担任财务副总裁兼秘书。她也是美国W.O.M.E.N。（专业开发团队，旨在提升有前途的职业女性）的活跃导师。
- Mary Garrett has served as a director of Omnicell since May 2022. Ms. Garrett is currently the President of M. Power Coaching and Consulting, LLC, a firm focused on developing executive leaders and helping organizations align brand and culture, customer experience and employee engagement for positive impact on business vitality and growth. Ms. Garrett has held this position since June 2018. From September 2008 until December 2015, Ms. Garrett served as the chief marketing officer, global markets at International Business Machines Corporation ("IBM"), a leading global provider of technology products and services. Prior to that, Ms. Garrett served in key positions of increasing authority and responsibility upon joining IBM in 1981 through August 2008. Ms. Garrett currently serves as a director of PROCEPT BioRobotics Corp., a surgical robotics company, and has served on the board of this company and as chair of its nominating and governance committee since December 2021. Ms. Garrett previously served as a director of Ethan Allen Interiors, Inc., a leading interior design company, manufacturer and retailer in the home furnishings marketplace, from January 2016 until November 2021, and was a member of the Audit Committee. She has also served as a director of Hillrom Corporation (subsequently acquired by Baxter International, Inc.), a global medical technology company, from March 2017 until December 2021, and was chair of the Nominating/Corporate Governance Committee and a member of the Audit Committee. Ms. Garrett received a B.S. in bio medical engineering from Boston University and an M.S. in bio electrical engineering from Brown University.
- Eileen J. Voynick
-
EileenJ.Voynick曾于2011年至2018年担任企业质量管理软件解决方案领先提供商Sparta Systems的首席执行官。加入Sparta Systems公司之前，她曾担任Allscripts公司的首席运营官。任职Allscripts公司之前，她曾担任Misys公司的负责全球销售、服务和支持的执行Vice President，也曾担任Oracle公司、SAP公司、Siebel Systems公司、Gartner公司、Ariba公司和埃森哲公司的多种管理职务。她于2016年至2018年担任AdvancedMD的董事，于2013年至2020年7月担任费城大学董事会主席，于2017年至2020年7月担任Jefferson Health的董事会和执行委员会成员并于2017年至2020年7月担任托马斯·杰斐逊大学董事会主席。
Eileen J. Voynick has served as a director of Omnicell since January 2024. Ms. Voynick served as Chief Executive Officer of Sparta Systems, a leading provider of enterprise quality management software solutions, from July 2011 to April 2018. Prior to joining Sparta Systems, she served as the Chief Operating Officer at Allscripts from 2009 until 2011. From 2007 until 2009, she served as Executive Vice President of global sales, services, and support at Misys. Ms. Voynick served in various management positions at Oracle, SAP, Siebel Systems, Gartner, Ariba and Accenture from 1994 until 2007. She served as a director at AdvancedMD from March 2016 to September 2018, as a member of the Board of Trustees and Executive Committee of Jefferson Health from 2017 to July 2020, as the Chair of the Board of Trustees of Philadelphia University from 2013 to July 2017, as a member of the Board of Trustees of Thomas Jefferson University from 2017 to July 2020 and as Chair of the Jefferson Academic Board of the Thomas Jefferson University from 2017 to 2019. Ms. Voynick previously served as Board Chair of AGS Health, a revenue cycle management provider, from April 2021 until August 2025. Ms. Voynick formerly served on the board of directors of Skydeck Acquisition Corp., a special purpose acquisition company, from April 2021 until April 2023, CDK Global, Inc., a leading provider of integrated data and technology solutions to the automotive, heavy truck, recreation and heavy equipment industries from June 2016 until July 2022 and r3, an enterprise blockchain technology company from June 2018 until June 2023. Ms. Voynick holds a B.S. in finance from Philadelphia University. - EileenJ.Voynick曾于2011年至2018年担任企业质量管理软件解决方案领先提供商Sparta Systems的首席执行官。加入Sparta Systems公司之前，她曾担任Allscripts公司的首席运营官。任职Allscripts公司之前，她曾担任Misys公司的负责全球销售、服务和支持的执行Vice President，也曾担任Oracle公司、SAP公司、Siebel Systems公司、Gartner公司、Ariba公司和埃森哲公司的多种管理职务。她于2016年至2018年担任AdvancedMD的董事，于2013年至2020年7月担任费城大学董事会主席，于2017年至2020年7月担任Jefferson Health的董事会和执行委员会成员并于2017年至2020年7月担任托马斯·杰斐逊大学董事会主席。
- Eileen J. Voynick has served as a director of Omnicell since January 2024. Ms. Voynick served as Chief Executive Officer of Sparta Systems, a leading provider of enterprise quality management software solutions, from July 2011 to April 2018. Prior to joining Sparta Systems, she served as the Chief Operating Officer at Allscripts from 2009 until 2011. From 2007 until 2009, she served as Executive Vice President of global sales, services, and support at Misys. Ms. Voynick served in various management positions at Oracle, SAP, Siebel Systems, Gartner, Ariba and Accenture from 1994 until 2007. She served as a director at AdvancedMD from March 2016 to September 2018, as a member of the Board of Trustees and Executive Committee of Jefferson Health from 2017 to July 2020, as the Chair of the Board of Trustees of Philadelphia University from 2013 to July 2017, as a member of the Board of Trustees of Thomas Jefferson University from 2017 to July 2020 and as Chair of the Jefferson Academic Board of the Thomas Jefferson University from 2017 to 2019. Ms. Voynick previously served as Board Chair of AGS Health, a revenue cycle management provider, from April 2021 until August 2025. Ms. Voynick formerly served on the board of directors of Skydeck Acquisition Corp., a special purpose acquisition company, from April 2021 until April 2023, CDK Global, Inc., a leading provider of integrated data and technology solutions to the automotive, heavy truck, recreation and heavy equipment industries from June 2016 until July 2022 and r3, an enterprise blockchain technology company from June 2018 until June 2023. Ms. Voynick holds a B.S. in finance from Philadelphia University.
- Edward P. Bousa
-
Edward P. Bousa，自2021年7月起担任全细胞医护科技董事。2005年至2020年6月，他是投资管理公司Wellington Management Company LLC的合伙人。在此之前，Bousa先生在2000年4月加入Wellington Management Company LLC后担任的职务越来越重要。Bousa先生曾于1992年至2000年在Putnam Investments，LLC担任共同基金经理。1983年至1992年，他在Fidelity Investments，Inc.担任股票研究分析师和投资组合经理。Bousa先生的职业生涯始于1980年至1982年在Louis Dreyfus Corporation担任商品跟单员。Bousa先生是一名特许金融分析师。他还自2024年8月起担任美国最大的退休解决方案和保险产品提供商之一Corebridge Financial, Inc.的董事，包括担任审计委员会成员，并自2025年3月起担任其薪酬委员会成员。Bousa先生此前曾于2024年1月至2025年1月期间担任Azenta, Inc.的董事，该公司是一家为生命科学行业提供生物和化学化合物样本探索和管理解决方案的全球领先供应商，并且是审计委员会以及环境、社会和治理委员会的成员。他获得了威廉姆斯学院的经济学学士学位和哈佛商学院的工商管理硕士学位。
Edward P. Bousa has served as a director of Omnicell since July 2021. He was a partner at Wellington Management Company LLC, an investment management firm, from 2005 until June 2020. Prior to that, Mr. Bousa held positions of increasing responsibility upon joining Wellington Management Company LLC in April 2000. Mr. Bousa was a mutual fund manager at Putnam Investments, LLC from 1992 to 2000. From 1983 to 1992, he was an equity research analyst and portfolio manager at Fidelity Investments, Inc. Mr. Bousa began his career as a commodity merchandiser at Louis Dreyfus Corporation from 1980 to 1982. Mr. Bousa is a Chartered Financial Analyst. He has also served as a director of Corebridge Financial, Inc., one of the largest providers of retirement solutions and insurance products in the United States, since August 2024, including as a member of the Audit Committee and has served as a member of its Compensation Committee since March 2025. He has also served as a director of Gartner, Inc., a leading Information Technology research and advisory company, since January 2026, including as a member of the Audit Committee. Mr. Bousa previously served as a director of Azenta, Inc., a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry, from January 2024 until January 2025, and was a member of the Audit and Environmental, Social and Governance Committees. He received a B.A. in economics from Williams College and an M.B.A. from the Harvard Business School. - Edward P. Bousa，自2021年7月起担任全细胞医护科技董事。2005年至2020年6月，他是投资管理公司Wellington Management Company LLC的合伙人。在此之前，Bousa先生在2000年4月加入Wellington Management Company LLC后担任的职务越来越重要。Bousa先生曾于1992年至2000年在Putnam Investments，LLC担任共同基金经理。1983年至1992年，他在Fidelity Investments，Inc.担任股票研究分析师和投资组合经理。Bousa先生的职业生涯始于1980年至1982年在Louis Dreyfus Corporation担任商品跟单员。Bousa先生是一名特许金融分析师。他还自2024年8月起担任美国最大的退休解决方案和保险产品提供商之一Corebridge Financial, Inc.的董事，包括担任审计委员会成员，并自2025年3月起担任其薪酬委员会成员。Bousa先生此前曾于2024年1月至2025年1月期间担任Azenta, Inc.的董事，该公司是一家为生命科学行业提供生物和化学化合物样本探索和管理解决方案的全球领先供应商，并且是审计委员会以及环境、社会和治理委员会的成员。他获得了威廉姆斯学院的经济学学士学位和哈佛商学院的工商管理硕士学位。
- Edward P. Bousa has served as a director of Omnicell since July 2021. He was a partner at Wellington Management Company LLC, an investment management firm, from 2005 until June 2020. Prior to that, Mr. Bousa held positions of increasing responsibility upon joining Wellington Management Company LLC in April 2000. Mr. Bousa was a mutual fund manager at Putnam Investments, LLC from 1992 to 2000. From 1983 to 1992, he was an equity research analyst and portfolio manager at Fidelity Investments, Inc. Mr. Bousa began his career as a commodity merchandiser at Louis Dreyfus Corporation from 1980 to 1982. Mr. Bousa is a Chartered Financial Analyst. He has also served as a director of Corebridge Financial, Inc., one of the largest providers of retirement solutions and insurance products in the United States, since August 2024, including as a member of the Audit Committee and has served as a member of its Compensation Committee since March 2025. He has also served as a director of Gartner, Inc., a leading Information Technology research and advisory company, since January 2026, including as a member of the Audit Committee. Mr. Bousa previously served as a director of Azenta, Inc., a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry, from January 2024 until January 2025, and was a member of the Audit and Environmental, Social and Governance Committees. He received a B.A. in economics from Williams College and an M.B.A. from the Harvard Business School.
- Bruce E. Scott
-
Bruce E. Scott，自2019年5月起担任全细胞医护科技的董事。2014年4月至2018年11月，Scott先生担任EnvisonRXOptions的EnvisionPharmacy部门总裁，EnvisonRXOptions是一家医疗保健和药房福利管理公司，是Rite Aid Corporation的子公司。从2008年9月到2012年4月，Scott先生在药房福利管理公司美可保健担任过多个行政职务，包括Accredo输液服务总裁、重症监护系统总裁以及高级副总裁兼首席药剂师。从2004年到2008年7月，Scott先生担任药房管理服务提供商McKesson Medication Management LLC的首席运营官。此前，他曾在Allina医院和诊所担任多个高级领导职务，包括1987年至1998年担任联合医院药学主任。斯科特先生担任威斯康星大学药学院访客委员会主席，该委员会是药学院的顾问委员会。斯科特先生获得了威斯康星大学的药学学士学位和堪萨斯大学的药学管理硕士学位，并在那里完成了药学住院医师项目。
Bruce E. Scott has served as a director of Omnicell since May 2019. From April 2014 to November 2018, Mr. Scott served as President of the EnvisionPharmacies division of EnvisonRxOptions, a healthcare and pharmacy benefit management company and a subsidiary of the Rite Aid Corporation. From September 2008 to April 2012, Mr. Scott held various executive roles at Medco Health Solutions, Inc., a pharmacy benefit management company, including President of Accredo Infusion Services, President of Critical Care Systems and Senior Vice President and Chief Pharmacist. From 2004 to July 2008, Mr. Scott was Chief Operating Officer of McKesson Medication Management LLC, a provider of pharmacy management services. Previously, he held several senior leadership roles at Allina Hospitals and Clinics, including as the Director of Pharmacy of United Hospital from 1987 to 1998. Mr. Scott currently serves on the University of Wisconsin, School of Pharmacy Board of Visitors, an advisory board for the School of Pharmacy and previously served as Chair from 2020 until 2024. Mr. Scott received a B.S. in pharmacy from the University of Wisconsin and an M.S. in pharmacy administration from the University of Kansas where he also completed a pharmacy residency program. - Bruce E. Scott，自2019年5月起担任全细胞医护科技的董事。2014年4月至2018年11月，Scott先生担任EnvisonRXOptions的EnvisionPharmacy部门总裁，EnvisonRXOptions是一家医疗保健和药房福利管理公司，是Rite Aid Corporation的子公司。从2008年9月到2012年4月，Scott先生在药房福利管理公司美可保健担任过多个行政职务，包括Accredo输液服务总裁、重症监护系统总裁以及高级副总裁兼首席药剂师。从2004年到2008年7月，Scott先生担任药房管理服务提供商McKesson Medication Management LLC的首席运营官。此前，他曾在Allina医院和诊所担任多个高级领导职务，包括1987年至1998年担任联合医院药学主任。斯科特先生担任威斯康星大学药学院访客委员会主席，该委员会是药学院的顾问委员会。斯科特先生获得了威斯康星大学的药学学士学位和堪萨斯大学的药学管理硕士学位，并在那里完成了药学住院医师项目。
- Bruce E. Scott has served as a director of Omnicell since May 2019. From April 2014 to November 2018, Mr. Scott served as President of the EnvisionPharmacies division of EnvisonRxOptions, a healthcare and pharmacy benefit management company and a subsidiary of the Rite Aid Corporation. From September 2008 to April 2012, Mr. Scott held various executive roles at Medco Health Solutions, Inc., a pharmacy benefit management company, including President of Accredo Infusion Services, President of Critical Care Systems and Senior Vice President and Chief Pharmacist. From 2004 to July 2008, Mr. Scott was Chief Operating Officer of McKesson Medication Management LLC, a provider of pharmacy management services. Previously, he held several senior leadership roles at Allina Hospitals and Clinics, including as the Director of Pharmacy of United Hospital from 1987 to 1998. Mr. Scott currently serves on the University of Wisconsin, School of Pharmacy Board of Visitors, an advisory board for the School of Pharmacy and previously served as Chair from 2020 until 2024. Mr. Scott received a B.S. in pharmacy from the University of Wisconsin and an M.S. in pharmacy administration from the University of Kansas where he also completed a pharmacy residency program.
- Kaushik Ghoshal
-
Kaushik Ghoshal，自2023年7月起担任全细胞医护科技董事。现任全球数字健康和云连接医疗设备领导者ResMed Inc.（“ResMed”）SaaS首席商务官，此前于2021年8月至2023年12月担任总裁— SaaS业务，并于2018年4月至2021年8月担任ResMed首席技术官。在此之前，Ghoshal先生曾于2016年6月至2018年4月担任Brightree LLC的首席运营官，该公司是ResMed旗下的院外护理基于云的SaaS提供商。从2012年到2016年，Ghoshal先生担任ResMed信息技术副总裁。在2012年之前，Ghoshal先生曾在飞思卡尔、摩托罗拉、Compuware和Wipro Infotech担任多个技术管理职位。Ghoshal先生拥有亚利桑那州立大学的工商管理硕士学位和印度卡利卡特国家理工学院的电子工程和电信学士学位。
Kaushik Ghoshal has served as a director of Omnicell since July 2023. He currently serves as Chief Executive Officer of Experity, Inc. ("Experity"), a leading software and services company for on demand healthcare in the U.S. urgent care market, and previously served as President of Experity from August 2025 until February 2026. Prior to this, he served as the Chief Commercial Officer, SaaS of ResMed Inc. ("ResMed"), a global leader in digital health and cloud connected medical devices from December 2023 until August 2025 and previously as President — SaaS Business from August 2021 to December 2023, and served as Chief Technology Officer of ResMed, from April 2018 until August 2021. Prior to that, Mr. Ghoshal served as Chief Operating Officer for Brightree LLC, a ResMed owned provider of cloud based SaaS for out of hospital care from June 2016 until April 2018. From 2012 until 2016, Mr. Ghoshal served as ResMed's Vice President, Information Technology. Prior to 2012, Mr. Ghoshal held a number of technology management positions with Freescale Semiconductor, Motorola, Compuware and Wipro Infotech. Mr. Ghoshal holds an M.B.A. from Arizona State University and a B.S. degree in electronics engineering and telecommunications from the National Institute of Technology in Calicut, India. - Kaushik Ghoshal，自2023年7月起担任全细胞医护科技董事。现任全球数字健康和云连接医疗设备领导者ResMed Inc.（“ResMed”）SaaS首席商务官，此前于2021年8月至2023年12月担任总裁— SaaS业务，并于2018年4月至2021年8月担任ResMed首席技术官。在此之前，Ghoshal先生曾于2016年6月至2018年4月担任Brightree LLC的首席运营官，该公司是ResMed旗下的院外护理基于云的SaaS提供商。从2012年到2016年，Ghoshal先生担任ResMed信息技术副总裁。在2012年之前，Ghoshal先生曾在飞思卡尔、摩托罗拉、Compuware和Wipro Infotech担任多个技术管理职位。Ghoshal先生拥有亚利桑那州立大学的工商管理硕士学位和印度卡利卡特国家理工学院的电子工程和电信学士学位。
- Kaushik Ghoshal has served as a director of Omnicell since July 2023. He currently serves as Chief Executive Officer of Experity, Inc. ("Experity"), a leading software and services company for on demand healthcare in the U.S. urgent care market, and previously served as President of Experity from August 2025 until February 2026. Prior to this, he served as the Chief Commercial Officer, SaaS of ResMed Inc. ("ResMed"), a global leader in digital health and cloud connected medical devices from December 2023 until August 2025 and previously as President — SaaS Business from August 2021 to December 2023, and served as Chief Technology Officer of ResMed, from April 2018 until August 2021. Prior to that, Mr. Ghoshal served as Chief Operating Officer for Brightree LLC, a ResMed owned provider of cloud based SaaS for out of hospital care from June 2016 until April 2018. From 2012 until 2016, Mr. Ghoshal served as ResMed's Vice President, Information Technology. Prior to 2012, Mr. Ghoshal held a number of technology management positions with Freescale Semiconductor, Motorola, Compuware and Wipro Infotech. Mr. Ghoshal holds an M.B.A. from Arizona State University and a B.S. degree in electronics engineering and telecommunications from the National Institute of Technology in Calicut, India.
- Randall A. Lipps
-
Randall A. Lipps，自从1992年9月Omnicell成立以来，他担任董事长和董事。自2002年10月以来，他担任其总裁兼首席执行官。从1989年到1992年，他担任ST.Holdings, Inc.（一个旅游和营销公司）的高级副总裁。从1987年到1989年，他担任AMR的子公司和美国航空公司（American Airlines, Inc.）的助理副总裁负责销售和运营。他获得南卫理公会大学（Southern Methodist University）的经济学学士学位和工商管理学士学位。
Randall A. Lipps has served as Chairman of the Board and a director of Omnicell since founding Omnicell in September 1992, and as its President and Chief Executive Officer since October 2002. From June 2013 to October 2018, Mr. Lipps was a director of Invuity, Inc., a medical device company. Mr. Lipps served as a member of the Board of Trustees of the American Nurses Foundation from April 2019 until June 2025. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University. - Randall A. Lipps，自从1992年9月Omnicell成立以来，他担任董事长和董事。自2002年10月以来，他担任其总裁兼首席执行官。从1989年到1992年，他担任ST.Holdings, Inc.（一个旅游和营销公司）的高级副总裁。从1987年到1989年，他担任AMR的子公司和美国航空公司（American Airlines, Inc.）的助理副总裁负责销售和运营。他获得南卫理公会大学（Southern Methodist University）的经济学学士学位和工商管理学士学位。
- Randall A. Lipps has served as Chairman of the Board and a director of Omnicell since founding Omnicell in September 1992, and as its President and Chief Executive Officer since October 2002. From June 2013 to October 2018, Mr. Lipps was a director of Invuity, Inc., a medical device company. Mr. Lipps served as a member of the Board of Trustees of the American Nurses Foundation from April 2019 until June 2025. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University.
- Robin G. Seim
-
Robin G. Seim，他于2006年2月加入Omnicell担任副总裁并在2006年3月被任命为首席财务官。2009年1月，他被任命为首席财务官和副总裁负责金融、政府和制造业。在2012年3月，他被任命为负责财务、管理和制造业的执行副总裁兼首席财务官。加入Omnicell之前，他担任几个技术公司的首席财务官，包括Villa Montage Systems, Inc. （1999年到2001年）、Candera, Inc.（2001年到2004年）和Mirra Inc.（2005年）。在1999年之前，他担任过一系列北电网络（Nortel Networks）、海湾网络（Bay Networks）和美国国际商用机器公司（IBM）。他获得萨克拉门托的加州州立大学（California State University）的会计学士学位。
Robin G. Seim has served as a director of Omnicell since March 2019. Mr. Seim initially joined Omnicell in January 2006 and served in various financial and operational leadership roles, including Chief Financial Officer from January 2006 to August 2015 and President of Global Automation and Medication Adherence from March 2016 until his retirement in March 2019. Prior to joining Omnicell, Mr. Seim served as Chief Financial Officer of several technology companies, including Villa Montage Systems, Inc. from 1999 to 2001, Candera, Inc. from 2001 to 2004 and Mirra, Inc., in 2005. Prior to 1999, Mr. Seim held a number of management positions with Nortel Networks, Bay Networks and IBM. Mr. Seim received a B.S. in accounting from California State University, Sacramento. - Robin G. Seim，他于2006年2月加入Omnicell担任副总裁并在2006年3月被任命为首席财务官。2009年1月，他被任命为首席财务官和副总裁负责金融、政府和制造业。在2012年3月，他被任命为负责财务、管理和制造业的执行副总裁兼首席财务官。加入Omnicell之前，他担任几个技术公司的首席财务官，包括Villa Montage Systems, Inc. （1999年到2001年）、Candera, Inc.（2001年到2004年）和Mirra Inc.（2005年）。在1999年之前，他担任过一系列北电网络（Nortel Networks）、海湾网络（Bay Networks）和美国国际商用机器公司（IBM）。他获得萨克拉门托的加州州立大学（California State University）的会计学士学位。
- Robin G. Seim has served as a director of Omnicell since March 2019. Mr. Seim initially joined Omnicell in January 2006 and served in various financial and operational leadership roles, including Chief Financial Officer from January 2006 to August 2015 and President of Global Automation and Medication Adherence from March 2016 until his retirement in March 2019. Prior to joining Omnicell, Mr. Seim served as Chief Financial Officer of several technology companies, including Villa Montage Systems, Inc. from 1999 to 2001, Candera, Inc. from 2001 to 2004 and Mirra, Inc., in 2005. Prior to 1999, Mr. Seim held a number of management positions with Nortel Networks, Bay Networks and IBM. Mr. Seim received a B.S. in accounting from California State University, Sacramento.
- Joanne B. Bauer
-
Joanne B. Bauer于2006年担任主管全球健康护理部的总裁。她对公司全球护理业务负责，包括各类外科及感染预防设备产品。Bauer女士于1981年加入公司。她过去担任职务的职责包括各类成人护理和健康护理业务的营销和管理。她在1996年被任命为KimFibers有限责任公司董事会副主席；于1998年担任主管健康护理全球营销的副总裁；于2001年担任健康护理部总裁。她是Omnicell股份有限公司、先进医疗技术协会（Advanced Medical Technology Association）、极光健康护理（Aurora Health Care）和MedShare公司董事。
Joanne B. Bauer has served as a director of Omnicell since January 2014. Since October 2013, Ms. Bauer has served as a Director of Advocate Health Inc. (and its predecessors Aurora Healthcare and Advocate Aurora Health), an integrated not for profit healthcare provider serving communities throughout eastern Wisconsin, northern Illinois, North Carolina and Georgia. From October 2001 until June 2014, Ms. Bauer served as President of Global Health Care at Kimberly Clark Corporation, a global consumer packaged goods company. Ms. Bauer joined Kimberly Clark in 1981 and held various marketing and management positions within its adult care and health care businesses. Ms. Bauer received a B.A. degree from Lawrence University and an M.B.A. from the University of Wisconsin, Oshkosh. - Joanne B. Bauer于2006年担任主管全球健康护理部的总裁。她对公司全球护理业务负责，包括各类外科及感染预防设备产品。Bauer女士于1981年加入公司。她过去担任职务的职责包括各类成人护理和健康护理业务的营销和管理。她在1996年被任命为KimFibers有限责任公司董事会副主席；于1998年担任主管健康护理全球营销的副总裁；于2001年担任健康护理部总裁。她是Omnicell股份有限公司、先进医疗技术协会（Advanced Medical Technology Association）、极光健康护理（Aurora Health Care）和MedShare公司董事。
- Joanne B. Bauer has served as a director of Omnicell since January 2014. Since October 2013, Ms. Bauer has served as a Director of Advocate Health Inc. (and its predecessors Aurora Healthcare and Advocate Aurora Health), an integrated not for profit healthcare provider serving communities throughout eastern Wisconsin, northern Illinois, North Carolina and Georgia. From October 2001 until June 2014, Ms. Bauer served as President of Global Health Care at Kimberly Clark Corporation, a global consumer packaged goods company. Ms. Bauer joined Kimberly Clark in 1981 and held various marketing and management positions within its adult care and health care businesses. Ms. Bauer received a B.A. degree from Lawrence University and an M.B.A. from the University of Wisconsin, Oshkosh.
- Mark W. Parrish
-
Mark W. Parrish，他一直担任Omnicell的董事（自2013年1月以来）。自2008年以来，他担任TridentUSA Health Services（为长期护理行业提供移动x射线及实验室服务的供应商）的主席兼首席执行官。2001年初，他担任Cardinal Health Inc.和其附属公司的管理职务并不断被提拔，包括Cardinal Health 的首席执行官（2006年到2007年）负责医疗供应链服务。他担任Mylan Inc.（一个全球制药公司）的董事、医药批发商国际联合会（the International Federation of Pharmaceutical Wholesalers）（一个药品批发商和药品供应链服务公司的协会）的主席和Frazier Healthcare Ventures（面向医疗的发展股权投资公司）的高级顾问。他获得了伯克利的Southern California大学的学士学位。
Mark W. Parrish has served as a director of Omnicell since January 2013. Mr. Parrish served as Chief Executive Officer of TridentUSA Health Services, a provider of mobile X ray and laboratory services to the long term care industry, from 2008 to August 2018, and as Executive Chairman of TridentUSA Health Service from August 2018 to September 2019. In February 2019, TridentUSA Health Services filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Commencing in 1993, Mr. Parrish held management roles of increasing significance with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as a director and Vice Chairman of Viatris, Inc. (formerly, Mylan N.V.), a global pharmaceutical company, as the Chairman of Safecor, a privately held hospital services firm. He also served as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies from 2013 until May 31, 2025. Mr. Parrish received a B.A. from the University of California, Berkeley. - Mark W. Parrish，他一直担任Omnicell的董事（自2013年1月以来）。自2008年以来，他担任TridentUSA Health Services（为长期护理行业提供移动x射线及实验室服务的供应商）的主席兼首席执行官。2001年初，他担任Cardinal Health Inc.和其附属公司的管理职务并不断被提拔，包括Cardinal Health 的首席执行官（2006年到2007年）负责医疗供应链服务。他担任Mylan Inc.（一个全球制药公司）的董事、医药批发商国际联合会（the International Federation of Pharmaceutical Wholesalers）（一个药品批发商和药品供应链服务公司的协会）的主席和Frazier Healthcare Ventures（面向医疗的发展股权投资公司）的高级顾问。他获得了伯克利的Southern California大学的学士学位。
- Mark W. Parrish has served as a director of Omnicell since January 2013. Mr. Parrish served as Chief Executive Officer of TridentUSA Health Services, a provider of mobile X ray and laboratory services to the long term care industry, from 2008 to August 2018, and as Executive Chairman of TridentUSA Health Service from August 2018 to September 2019. In February 2019, TridentUSA Health Services filed for protection under Chapter 11 of the U.S. Bankruptcy Code. Commencing in 1993, Mr. Parrish held management roles of increasing significance with Cardinal Health Inc. and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as a director and Vice Chairman of Viatris, Inc. (formerly, Mylan N.V.), a global pharmaceutical company, as the Chairman of Safecor, a privately held hospital services firm. He also served as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies from 2013 until May 31, 2025. Mr. Parrish received a B.A. from the University of California, Berkeley.
高管简历
中英对照 | 中文 | 英文- Baird Radford
Baird Radford，在加入全细胞医护科技之前，Radford先生于2021年4月至2025年5月期间担任Allakos，Inc.的首席财务官，该公司是一家为患有慢性疾病的个人开发单克隆抗体的生物技术公司。2020年1月至2021年2月，Radford先生担任Aimmune治疗公司财务高级副总裁，在雀巢健康科学收购该公司后离职。2014年7月至2020年1月，Radford先生担任HeartFlow，Inc.的首席财务官，HeartFlow，Inc.是一家商业阶段的软件服务公司，适用于诊断和管理冠状动脉疾病的人工智能。在加入HeartFlow之前，Radford先生曾在直觉外科公司担任财务副总裁，并在eBay Inc.担任过多个职务，包括欧洲财务副总裁以及副总裁公司财务总监和首席会计官。Radford先生在获得俄亥俄大学工商管理学士学位后，开始了他在普华永道会计师事务所审计实践的职业生涯。
Baird Radford,Prior to joining Omnicell, Mr. Radford served as Chief Financial Officer of Allakos, Inc., a biotech company developing monoclonal antibodies for individuals with chronic conditions, from April 2021 to May 2025. From January 2020 to February 2021, Mr. Radford served as Senior Vice President of Finance of Aimmune Therapeutics Inc., exiting following the acquisition of the company by Nestle Health Science. From July 2014 to January 2020, Mr. Radford served as Chief Financial Officer of HeartFlow, Inc., a commercial-stage software services company Omnicell, Inc. ing artificial intelligence for diagnosing and managing coronary artery disease. Prior to HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, Inc. and held various roles at eBay Inc., including Vice President of European Finance as well as Vice President Corporate Controller and Chief Accounting Officer. Mr. Radford began his professional career in the audit practice of PricewaterhouseCoopers after receiving his Bachelor of Business Administration degree from Ohio University.- Baird Radford，在加入全细胞医护科技之前，Radford先生于2021年4月至2025年5月期间担任Allakos，Inc.的首席财务官，该公司是一家为患有慢性疾病的个人开发单克隆抗体的生物技术公司。2020年1月至2021年2月，Radford先生担任Aimmune治疗公司财务高级副总裁，在雀巢健康科学收购该公司后离职。2014年7月至2020年1月，Radford先生担任HeartFlow，Inc.的首席财务官，HeartFlow，Inc.是一家商业阶段的软件服务公司，适用于诊断和管理冠状动脉疾病的人工智能。在加入HeartFlow之前，Radford先生曾在直觉外科公司担任财务副总裁，并在eBay Inc.担任过多个职务，包括欧洲财务副总裁以及副总裁公司财务总监和首席会计官。Radford先生在获得俄亥俄大学工商管理学士学位后，开始了他在普华永道会计师事务所审计实践的职业生涯。
- Baird Radford,Prior to joining Omnicell, Mr. Radford served as Chief Financial Officer of Allakos, Inc., a biotech company developing monoclonal antibodies for individuals with chronic conditions, from April 2021 to May 2025. From January 2020 to February 2021, Mr. Radford served as Senior Vice President of Finance of Aimmune Therapeutics Inc., exiting following the acquisition of the company by Nestle Health Science. From July 2014 to January 2020, Mr. Radford served as Chief Financial Officer of HeartFlow, Inc., a commercial-stage software services company Omnicell, Inc. ing artificial intelligence for diagnosing and managing coronary artery disease. Prior to HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, Inc. and held various roles at eBay Inc., including Vice President of European Finance as well as Vice President Corporate Controller and Chief Accounting Officer. Mr. Radford began his professional career in the audit practice of PricewaterhouseCoopers after receiving his Bachelor of Business Administration degree from Ohio University.
- Nnamdi Njoku
Nnamdi Njoku，2024年10月加入全细胞医护科技，担任执行副总裁兼首席运营官。在加入全细胞医护科技之前，Njoku先生于2023年3月至2024年9月期间担任全球医疗技术领导者齐默巴奥米特控股公司的运动医学、外科、上肢和修复疗法总裁。2022年4月至2023年3月，Njoku先生在美敦力公司担任高级副总裁兼总裁–神经调节，该公司是全球领先的医疗保健技术公司（“美敦力”）—— TERM3，即美敦力 PLC的子公司。在此之前，他曾于2019年8月至2022年3月在美敦力担任总裁–机械循环支持，于2018年2月至2019年8月担任副总裁兼总经理–变革性解决方案，并于2017年9月至2018年10月担任外科协同副总裁。从2005年8月至2017年8月，Njoku先生在美敦力担任执行运营职务，负责不断增加的责任。在加入美敦力之前，Njoku先生曾在联合健康和德勤咨询公司担任运营职务，承担越来越大的责任。Njoku先生获得圣托马斯大学工商管理文学士学位和康奈尔大学MBA学位。
Nnamdi Njoku served as Executive Vice President and Chief Operating Officer of the Company from October 2024 until June 2026. Prior to joining Omnicell, Mr. Njoku served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc., a global medical technology leader, from March 2023 to September 2024. From April 2022 to March 2023, Mr. Njoku served as Senior Vice President & President – Neuromodulation at Medtronic, Inc., a subsidiary of Medtronic plc, a leading global healthcare technology company ("Medtronic"). Prior to that, he served as President – Mechanical Circulatory Support from August 2019 to March 2022, as Vice President & General Manager – Transformative Solutions from February 2018 to August 2019 and as Vice President, Surgical Synergy from September 2017 to October 2018 at Medtronic. From August 2005 to August 2017, Mr. Njoku held executive operational roles of increasing responsibility at Medtronic. Prior to Medtronic, Mr. Njoku served in operational roles of increasing responsibility at UnitedHealth Group and Deloitte Consulting. Mr. Njoku received a Bachelor of Arts degree in business administration from the University of St. Thomas and an MBA from Cornell University.- Nnamdi Njoku，2024年10月加入全细胞医护科技，担任执行副总裁兼首席运营官。在加入全细胞医护科技之前，Njoku先生于2023年3月至2024年9月期间担任全球医疗技术领导者齐默巴奥米特控股公司的运动医学、外科、上肢和修复疗法总裁。2022年4月至2023年3月，Njoku先生在美敦力公司担任高级副总裁兼总裁–神经调节，该公司是全球领先的医疗保健技术公司（“美敦力”）—— TERM3，即美敦力 PLC的子公司。在此之前，他曾于2019年8月至2022年3月在美敦力担任总裁–机械循环支持，于2018年2月至2019年8月担任副总裁兼总经理–变革性解决方案，并于2017年9月至2018年10月担任外科协同副总裁。从2005年8月至2017年8月，Njoku先生在美敦力担任执行运营职务，负责不断增加的责任。在加入美敦力之前，Njoku先生曾在联合健康和德勤咨询公司担任运营职务，承担越来越大的责任。Njoku先生获得圣托马斯大学工商管理文学士学位和康奈尔大学MBA学位。
- Nnamdi Njoku served as Executive Vice President and Chief Operating Officer of the Company from October 2024 until June 2026. Prior to joining Omnicell, Mr. Njoku served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc., a global medical technology leader, from March 2023 to September 2024. From April 2022 to March 2023, Mr. Njoku served as Senior Vice President & President – Neuromodulation at Medtronic, Inc., a subsidiary of Medtronic plc, a leading global healthcare technology company ("Medtronic"). Prior to that, he served as President – Mechanical Circulatory Support from August 2019 to March 2022, as Vice President & General Manager – Transformative Solutions from February 2018 to August 2019 and as Vice President, Surgical Synergy from September 2017 to October 2018 at Medtronic. From August 2005 to August 2017, Mr. Njoku held executive operational roles of increasing responsibility at Medtronic. Prior to Medtronic, Mr. Njoku served in operational roles of increasing responsibility at UnitedHealth Group and Deloitte Consulting. Mr. Njoku received a Bachelor of Arts degree in business administration from the University of St. Thomas and an MBA from Cornell University.
- Corey J. Manley
Corey J. Manley，2021年4月加入全细胞医护科技，担任副总裁兼总法律顾问。2022年5月，Manley先生被任命为高级副总裁兼首席法务官。随后，在2023年6月，Manley先生被任命为执行副总裁兼首席法律和行政官。在加入全细胞医护科技之前，他于2018年4月至2021年4月在全球金融科技公司BFS资本公司担任首席法务官、公司秘书和首席合规官。从2014年8月至2018年4月，Manley先生是Duane Morris LLP律师事务所的合伙人，在此之前，他从2009年11月至2014年8月是Kirkland & Ellis LLP律师事务所的合伙人。Manley先生拥有圣母大学法学院法学博士学位和普渡大学机械工程学士学位。
Corey J. Manley,joined Omnicell in April 2021 as Vice President and General Counsel. In May 2022, Mr. Manley was named Senior Vice President and Chief Legal Officer. Subsequently, in June 2023, Mr. Manley was named Executive Vice President and Chief Legal and Administrative Officer. Prior to joining Omnicell, he was Chief Legal Officer, Corporate Secretary, and Chief Compliance Officer with BFS Capital, Inc., a global fintech company, from April 2018 to April 2021. From August 2014 until April 2018, Mr. Manley was a partner in the law firm of Duane Morris LLP and prior to that he was a partner in the law firm of Kirkland & Ellis LLP from November 2009 until August 2014. Mr. Manley holds a J.D. from the University of Notre Dame Law School and a B.S. in mechanical engineering from Purdue University.- Corey J. Manley，2021年4月加入全细胞医护科技，担任副总裁兼总法律顾问。2022年5月，Manley先生被任命为高级副总裁兼首席法务官。随后，在2023年6月，Manley先生被任命为执行副总裁兼首席法律和行政官。在加入全细胞医护科技之前，他于2018年4月至2021年4月在全球金融科技公司BFS资本公司担任首席法务官、公司秘书和首席合规官。从2014年8月至2018年4月，Manley先生是Duane Morris LLP律师事务所的合伙人，在此之前，他从2009年11月至2014年8月是Kirkland & Ellis LLP律师事务所的合伙人。Manley先生拥有圣母大学法学院法学博士学位和普渡大学机械工程学士学位。
- Corey J. Manley,joined Omnicell in April 2021 as Vice President and General Counsel. In May 2022, Mr. Manley was named Senior Vice President and Chief Legal Officer. Subsequently, in June 2023, Mr. Manley was named Executive Vice President and Chief Legal and Administrative Officer. Prior to joining Omnicell, he was Chief Legal Officer, Corporate Secretary, and Chief Compliance Officer with BFS Capital, Inc., a global fintech company, from April 2018 to April 2021. From August 2014 until April 2018, Mr. Manley was a partner in the law firm of Duane Morris LLP and prior to that he was a partner in the law firm of Kirkland & Ellis LLP from November 2009 until August 2014. Mr. Manley holds a J.D. from the University of Notre Dame Law School and a B.S. in mechanical engineering from Purdue University.
- Randall A. Lipps
Randall A. Lipps，自从1992年9月Omnicell成立以来，他担任董事长和董事。自2002年10月以来，他担任其总裁兼首席执行官。从1989年到1992年，他担任ST.Holdings, Inc.（一个旅游和营销公司）的高级副总裁。从1987年到1989年，他担任AMR的子公司和美国航空公司（American Airlines, Inc.）的助理副总裁负责销售和运营。他获得南卫理公会大学（Southern Methodist University）的经济学学士学位和工商管理学士学位。
Randall A. Lipps has served as Chairman of the Board and a director of Omnicell since founding Omnicell in September 1992, and as its President and Chief Executive Officer since October 2002. From June 2013 to October 2018, Mr. Lipps was a director of Invuity, Inc., a medical device company. Mr. Lipps served as a member of the Board of Trustees of the American Nurses Foundation from April 2019 until June 2025. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University.- Randall A. Lipps，自从1992年9月Omnicell成立以来，他担任董事长和董事。自2002年10月以来，他担任其总裁兼首席执行官。从1989年到1992年，他担任ST.Holdings, Inc.（一个旅游和营销公司）的高级副总裁。从1987年到1989年，他担任AMR的子公司和美国航空公司（American Airlines, Inc.）的助理副总裁负责销售和运营。他获得南卫理公会大学（Southern Methodist University）的经济学学士学位和工商管理学士学位。
- Randall A. Lipps has served as Chairman of the Board and a director of Omnicell since founding Omnicell in September 1992, and as its President and Chief Executive Officer since October 2002. From June 2013 to October 2018, Mr. Lipps was a director of Invuity, Inc., a medical device company. Mr. Lipps served as a member of the Board of Trustees of the American Nurses Foundation from April 2019 until June 2025. Mr. Lipps received both a B.S. in economics and a B.B.A. from Southern Methodist University.
- Brian H. Nutt
Brian H. Nutt自2014年1月任Covance公司主要会计人员及公司外部报告高级董事，并自2011年5月曾任主要会计专员及公司外部报告董事。Nutt先生自2010年至2011年任公司金融董事。在此之前，Nutt先生曾为公司高级金融管理人员。在2006年加入Covance公司之前，Nutt先生在多个企业担任要职其中包括MedPointe医药公司、Carter-Wallace公司及KPMG公司。
Brian H. Nutt, has been Covance's Principal Accounting Officer and Senior Director of External Reporting since January 2014 and had been Principal Accounting Officer and Director of External Reporting since May 2011. Mr. Nutt was Director, Corporate Finance from 2010 to 2011. Prior to that, Mr. Nutt was a Senior Manager, Corporate Finance. Prior to joining Covance in 2006 Mr. Nutt held positions of increasing responsibility at a number of companies including MedPointe Pharmaceuticals, Carter-Wallace and KPMG.- Brian H. Nutt自2014年1月任Covance公司主要会计人员及公司外部报告高级董事，并自2011年5月曾任主要会计专员及公司外部报告董事。Nutt先生自2010年至2011年任公司金融董事。在此之前，Nutt先生曾为公司高级金融管理人员。在2006年加入Covance公司之前，Nutt先生在多个企业担任要职其中包括MedPointe医药公司、Carter-Wallace公司及KPMG公司。
- Brian H. Nutt, has been Covance's Principal Accounting Officer and Senior Director of External Reporting since January 2014 and had been Principal Accounting Officer and Director of External Reporting since May 2011. Mr. Nutt was Director, Corporate Finance from 2010 to 2011. Prior to that, Mr. Nutt was a Senior Manager, Corporate Finance. Prior to joining Covance in 2006 Mr. Nutt held positions of increasing responsibility at a number of companies including MedPointe Pharmaceuticals, Carter-Wallace and KPMG.